Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$63.29 USD
-2.96 (-4.47%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $65.18 +1.89 (2.99%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MNPR 63.29 -2.96(-4.47%)
Will MNPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength
Other News for MNPR
Jack-in-the-box Bullish appears for MNPR after 0.59% move
MNPR makes New 52 Week Closing High on September 18
New 52 Week Closing High appears for MNPR after 4.61% move
Raymond James Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
Is MNPR likely to continue higher? New 52 Week Closing High shows up after rallying 10.71%